The Two Weeks Around Cancer Surgery
If you have cancer surgery on the calendar, the two weeks around it may matter more than most people realize.
Breast cancer relapse data have shown the same pattern for decades. Recurrences cluster in an early wave in the months after surgery, then a second, smaller peak years later. Part of that early wave may be driven by the surgery itself.
This is not an argument against surgery. Surgery removes the tumor, and for most localized cancers it remains the cornerstone of curative care. The point is that cutting sets off a predictable stress response. Adrenaline and inflammatory signals surge, natural killer cells that hunt circulating tumor cells are suppressed, and tumor cells are shed into the blood. For roughly two weeks, the terrain tilts in favor of anything left behind.
What makes this exciting is that the window has a start date. We know when it opens, so we can plan for it.
Researchers have tested cheap, decades-old medications in this window. In a small randomized trial in early breast cancer, eleven days of propranolol plus an anti-inflammatory shifted tumor and blood markers in exactly the direction you would want. A small colorectal trial showed fewer recurrences at eight years. These are early signals, not proof, and any medication here has to be coordinated with your surgeon and anesthesiologist.
Other levers aim at the same biology. Omega-3 fatty acids feed the body's own off-switch for the inflammatory surge, and aspirin is being studied in a large ongoing trial across tumor types.
I believe the perioperative window is one of the most underused opportunities in oncology. It falls between the surgeon, the oncologist and the anesthesiologist, and nobody fully owns it.
If you have surgery coming up, start the conversation early. Book a free 15-minute consult, in person on Capitol Hill in Seattle or by telehealth in Washington and Oregon.




Comments